Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
TAG Mail 13 April 2016 The purpose of TAG Mail is to assist TAG members identify and share relevant information for their professional practice. Members are encouraged to routinely forward TAG Mail to others who they believe would benefit from this information such as colleagues in the same hospital department if they are not already receiving TAG Mail. NSW TAG RECRUITMENT - NSW TAG eMeds Project Officer A position is currently being advertised for a full-time 2-year contract project officer at NSW TAG. The aim of the project is to ensure that quality use of medicines principles are embedded in electronic medicines systems in NSW public hospitals. Salary will align with NSW Pharmacist Grade 4 award. Closing date: 22nd April 2016. See http://www.seek.com.au/Job/30656904?_ga=1.172695075.1413446636.1458771173 or http://careers.shpa.org.au/job/nsw-tag-electronic-medication-management-emeds-project-officer/ REPORTS AND PUBLICATIONS – AUSTRALIA **NSW Health - NSW Hospital Peer Groups http://www0.health.nsw.gov.au/policies/ib/2016/IB2016_013.html **AIHW - National Opioid Pharmacotherapy Statistics Annual Data (NOPSAD) collection 2015-16 http://www.aihw.gov.au/alcohol-and-other-drugs/nopsad/ **TGA - Flu vaccine: 2016 seasonal influenza vaccines for use in children http://www.tga.gov.au/alert/flu-vaccine-2016-seasonal-influenza-vaccines-use-children - Update to the list of designated orphan drugs: Pegaspargase (Pegaspar TM) for the treatment of patients with acute lymphoblastic leukaemia who require L-asparaginase in their treatment regimen, but have developed hypersensitivity to the native forms of L-asparaginase http://www.tga.gov.au/updates-list-designated-orphan-drugs - Consultation: Proposed amendments to the Poisons Standard, July 2016 (medicines). Closes 6 May 2016 http://www.tga.gov.au/consultation-invitation/consultation-proposed-amendments-poisons-standard-july2016-medicines - Advisory Committee on Prescription Medications (ACPM) Meeting Statement, Meeting 308, February 2016 http://www.tga.gov.au/committee-meeting-info/acpm-meeting-statement-meeting-308-5-february-2016 - AusPAR added: Eltrombopag (RevoladeTM) extension of indications to include the treatment of adult patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive therapy. http://www.tga.gov.au/auspar/auspar-eltrombopag - AusPAR added: Follitropin alpha (rch)( Bemfola/AfoliaTM) biosimilar medicine and extension of indications. http://www.tga.gov.au/auspar/auspar-follitropin-alfa-rch REPORTS AND PUBLICATIONS – INTERNATIONAL **FDA - Venetoclax (VenclextaTM) approved for the treatment of patients with chronic lymphocytic leukemia (CLL) who have a chromosomal abnormality called 17p deletion and who have been treated with at least one prior therapy. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm495253.htm - InflectraTM (infliximab-dyyb) approved as a biosimilar to RemicadeTM http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm494227.htm - Recall: G4 Platinum and G5 Mobile Continuous Glucose Monitoring System Receivers by Dexcom - Audible Alarm Failure http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm49546 8.htm **SIGN Chronic heart failure – patient booklet http://www.sign.ac.uk/patients/publications/147/index.html MEDICATION SAFETY **FDA - Drug safety communication: Diabetes medicines containing saxagliptin and alogliptin may increase the risk of heart failure, particularly in patients who already have heart or kidney disease http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm49425 2.htm - Drug safety communication: Metformin containing drugs – revised warning for patients with mild to moderate renal impairment http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm49482 9.htm **Health Quality and Safety Commission New Zealand - Medication Safety Watch Issue 17, April 2016 http://www.hqsc.govt.nz/assets/Medication-Safety/Watch-Updates/Medication-Safety-Watch-Issue-17.pdf PAPERS OF INTEREST **Annals of Internal Medicine - Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement http://annals.org/article.aspx?articleid=2513179 **British Journal of Clinical Pharmacology - Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's Disease http://onlinelibrary.wiley.com/doi/10.1111/bcp.12964/abstract - Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226 http://onlinelibrary.wiley.com/doi/10.1111/bcp.12904/abstract - Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers http://onlinelibrary.wiley.com/doi/10.1111/bcp.12912/abstract **BMJ - Early administration of epinephrine (adrenaline) in patients with cardiac arrest with initial shockable rhythm in hospital: propensity score matched analysis http://www.bmj.com/content/353/bmj.i1577 **BMJ Quality and Safety - ‘Smart’ intravenous pumps: how smart are they? http://qualitysafety.bmj.com/content/early/2016/04/07/bmjqs-2016-005302.full **European Heart Journal - The ‘obesity paradox’ in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial http://eurheartj.oxfordjournals.org/content/early/2016/04/11/eurheartj.ehw124 **EJHP - Patient-centred consultations in a dispensary setting: a learning journey http://ejhp.bmj.com/content/early/2016/04/05/ejhpharm-2016-000929.short?g=w_ejhp_ahead_tab **International Journal for Quality in Health Care - eHealth and quality in health care: implementation time http://intqhc.oxfordjournals.org/content/early/2016/03/29/intqhc.mzw032 **JAMA - Effect of Dexmedetomidine Added to Standard Care on Ventilator-Free Time in Patients with Agitated Delirium: A Randomized Clinical Trial http://jama.jamanetwork.com/article.aspx?articleid=2503421 **JAMA Intern Med - Preventability and Causes of Readmissions in a National Cohort of General Medicine Patients http://archinte.jamanetwork.com/article.aspx?articleid=2498846 **JAMA Psychiatry - Hydromorphone Compared With Diacetylmorphine for Long-term Opioid Dependence: A Randomized Clinical Trial http://archpsyc.jamanetwork.com/article.aspx?articleid=2512237 **JAMIA - Data and the clinical decision support loop http://jamia.oxfordjournals.org/content/23/e1/e1 - Real-time prediction of inpatient length of stay for discharge prioritization http://jamia.oxfordjournals.org/content/23/e1/e2 - Patient and physician predictors of patient receipt of therapies recommended by a computerized decision support system when initially prescribed broad-spectrum antibiotics: a cohort study http://jamia.oxfordjournals.org/content/23/e1/e58 - Provider variation in responses to warnings: do the same providers run stop signs repeatedly? http://jamia.oxfordjournals.org/content/23/e1/e93 - Experience with decision support system and comfort with topic predict clinicians’ responses to alerts and reminders http://jamia.oxfordjournals.org/content/23/e1/e125 **Neurology - Lamotrigine use in pregnancy and risk of orofacial cleft and other congenital anomalies http://www.neurology.org/content/early/2016/04/06/WNL.0000000000002540 **NEJM - Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting http://www.nejm.org/doi/full/10.1056/NEJMra1515442 - Pioglitazone after Ischemic Stroke or Transient Ischemic Attack http://www.nejm.org/doi/full/10.1056/NEJMoa1506930 OTHER NEWS Nil UPCOMING EVENTS (new additions in bold) **Toxicology and Poisons Network Australasia (TAPNA) Conference 2016 5 - 7 May 2016, Royal on the Park Hotel, Brisbane https://willorganise.eventsair.com/QuickEventWebsitePortal/2016-tapna-conference/website **National Medicines Symposium 2016 (NMS 2016), 18–20 May 2016, Canberra. Making wise decisions about medicines, tests and technologies: co-designing policy, practice and priorities http://www.nps.org.au/about-us/what-we-do/campaigns-events/national-medicines-symposium/program **The Laboratory of Innovative Practices on Polypharmacy and Health 3rd International Short Film and Photography Festival, May 2016 Entries close 30 April 2016 http://polimedicado.org **Pain Management Research Institute - Treatment Adherence Symposium 1 July 2016, Charles Perkins Centre Auditorium, University of Sydney http://sydney.edu.au/medicine/pmri/education/continuing/symposia.php **76th FIP World Congress of Pharmacy and Pharmaceutical Sciences 2016: Rising to the challenge: reducing the global burden of disease. Buenos Aires, Argentina, 28 August - 1 September 2016 http://buenosaires2016.fip.org/ **APAC Forum ‘Exploring new frontiers’ 12-14 September 2016, Sydney, NSW http://koawatea.co.nz/apac-forum/ **International Forum on Quality and Safety in Healthcare: Asia 26-28 September 2016, Singapore. http://internationalforumasia.bmj.com/ **Australian Disease Management Association 12th Annual National Conference “Person Centred Healthcare: Achievements & Challenges”, 20-12 October 2016, Melbourne Abstract submission closes 27 May 2016 http://www.adma.org.au/images/ConferenceFlyer_2016.pdf **SHPA Medicines Management 2016 Conference 16-19 November 2016, Perth Convention and Exhibition Centre, WA http://cpd.shpa.org.au/Conferences/Medicines-Management---SHPA-National-Conference You are receiving this email because you or a workplace colleague has requested TAG Mail. NSW TAG analyses uptake of TAG Mail (email openings and clicks on specific contents) in order to optimise the TAG Mail service for our members and colleagues. By requesting TAG Mail, you are also agreeing to have your data (email address, country of abode) captured. All information obtained is used in accordance with NSW Health Privacy Policy. Please contact NSW TAG at [email protected] if you have any questions regarding this.